Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Instrument | Transaction Date | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (25p) | January 10, 2019 | £15.2995 | 1,529 shares | London Stock Exchange |
Note: Total volume is the aggregate of three separate transactions reported in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by insiders via dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of share acquisitions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares resulting from the reinvestment of dividends paid on January 10, 2019.
- Parties Involved:
- Mrs. V A Whyte (Company Secretary): Acquired 111 shares.
- Mr. I W Whyte (PCA of Company Secretary): Acquired 522 shares.
- Ms. D Connor (PCA of President, Global Vaccines): Acquired 896 shares.
- Execution Price: All shares were acquired at a uniform price of £15.2995.
- Reporting Limitation: This filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.